The first RV formulation was withdrawn in 1999 due to its association with intussusception, 6 an acute and serious enfolding of the intestine which can result in bowel obstruction or loss of blood supply to the intestine. Although large pre-licensure clinical trials of the new RV5 and RV1 ruled out intussusception risks equal to that of the previous RV, a post-market case-control study found increased risks of intussusception in Brazilian and Mexican infants vaccinated with RV1, and a post-market cohort study of Australian infants found increased risks of intussusception following vaccination with RV1 and RV5 compared to unvaccinated infants. [7] [8] [9] However, studies demonstrating the increased risk of RV-associated intussusception have been inconsistent across different populations. In three large studies of US children, one RV1 showed an increased risk compared to historical background rates, 10 another showed no increase for RV5 compared to unvaccinated children, 11 and another did show increases with RV5
but inconclusive results about RV1. 12 In addition, natural rates of intussusception vary widely between countries, sexes, and age groups. [13] [14] [15] [16] [17] [18] [19] In addition to intussusception, some case reports suggest that natural rotavirus infection may be associated with conditions such as encephalitis and seizures, [20] [21] [22] which raises safety concerns for live rotavirus vaccinations. However, these hypothesised adverse events
have not been observed in connection with RV in large, population studies. Given concerns about RV-induced intussusception, the recommended RV administration during the peak ages of natural intussusception incidence, and the scarce safety data directly comparing RV5 to RV1 in US infants for other safety outcomes, we sought to analyse a large cohort of US infants using carefully developed methods to evaluate the safety of RV, overall and by vaccine formulation.
| ME THODS

| Data source and population
We identified newborns at birth in the MarketScan Commercial These administrative databases contain insurance billing claims and enrolment information for employees, spouses, and dependents from over 100 employer-sponsored insurance plans from throughout the United States.
Newborns were identified with International Classification of
Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes for livebirth (V30-V39). 23 We required continuous health plan enrolment from birth until the vaccination event, although we allowed a 7-day postbirth grace period for the beginning of continuous coverage to allow for initial plan enrolment.
| Exposure assessment
We anchored all our RV assessments and analyses on the receipt of a diphtheria-tetanus-pertussis (DTaP) vaccine dose; newborns were followed from the date of birth to 1 year of age to observe DTaP doses and determine if RV was administered on the same day.
Infant DTaP coverage is very high in the United States, 24 and DTaP and RV are frequently received together in the same visit; RV and DTaP follow similar dosing schedules, with recommended doses at 2, 4, and 6 months (except for the two-dose RV1 which does not have a 6-month dose) with doses at least 4 weeks apart. We identified infants who received at least one dose of DTaP vaccine, and we included up to three DTaP doses per infant in the study, creating a separate record for each dose ( Figure 1 ). We identified the receipt of DTaP vaccines in insurance claims using Current Procedure 
Study design schematic of pre-and post-vaccination observation periods for diphtheria-tetanus-pertussis (DTaP) doses and concurrent rotavirus vaccination (RV) of a hypothetical infant from birth to 1 y series of RV1 and RV5, incomplete RV series, and delayed RV doses (eg, the first RV dose received at the second DTaP vaccination).
| Outcome assessment
We defined study outcomes using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes and procedure coding for events occurring on the day of and in the 30 days after vaccination. Intussusception was identified through an inpatient diagnosis code for intussusception or a procedure code for a therapeutic enema to correct intussusception. 25 Other events identified during 30 days post-vaccination included: gastrointestinal events, including diarrhoea, blood in stool, and appendicitis; Kawasaki disease; neurological events, including seizure, meningitis, encephalitis, and febrile convulsions; thrombocytopenia; otitis media; all-cause hospitalisation; and all-cause emergency room visits (Table S1 ). We also identified events occurring in the 30 days prior to vaccination, allowing us to exclude those with pre-existing disease, ensuring identification of new-onset outcomes post-vaccination.
Previous research has suggested an increased risk of intussusception in the 7-day post-vaccination; 10, 26 additionally, some study outcomes are relatively common in early childhood, and events 30 days after vaccination may be less-likely to be attributable to the vaccination. Therefore, we performed a sensitivity analysis using a shorter, 7-day follow-up period rather than the full 30 days for some outcomes, including intussusception, seizures, diarrhoea, blood in stool otitis media, all-cause emergency department visits, and allcause hospitalisation.
| Covariate assessment
We assessed infant characteristics to account for potential differences between treatment groups, including sex, age at dose receipt, geographic region, and year. As many vaccinations can be received at the same visit, and several other vaccines are indicated in infants of the same age, we also assessed concurrent vaccination with the following: hepatitis B, Haemophilus influenzae type B, polio, pneumococcal, and influenza. dose-specific estimates, and then pooled estimates across doses using fixed-effect meta-analysis models to obtain overall estimates.
| Statistical analysis
Infants could be included in the separate analyses of all 3 doses.
Individual doses were excluded if the child was diagnosed with In addition, we assessed safety differences by RV formulation, comparing RV5 + DTaP to RV1+DTaP within doses 1 and 2. For the comparison of dose 2, we required the RV formulation to be the same for dose 1 and dose 2 (eg, a non-mixed series of either RV1 or RV5). As RV1 is a two-dose series, we did not perform a dose 3
comparison.
The analysis was approved by the institutional review board of the University of North Carolina at Chapel Hill. Individual consent was not required for this secondary analysis of deidentified data.
Analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).
| RE SULTS
We identified 1 031 431 infants receiving at least one dose of DTaP (51.6% male; mean age at first DTaP dose = 11.2 weeks, SD Of all the concurrent RV doses, 94.1% were RV5. Concurrent RV receipt increased over the study period, from 37.0% in 2006 to 90.5% in 2014. (Table 1; Table S2 ). There were differences in geographic distributions between the RV receivers and non-receivers, with RV being more common in the South and less common in the Northeast.
The RV1 and RV5 receivers were very similar in terms of sex, age, and US region, although RV1 was introduced later in the study period.
Co-administration of other vaccines varied between the RV+DTaP and the DTaP alone groups, both within a dose (Table 1 ) and across doses (Table S2 ).
The incidence of post-vaccination outcomes varied widely. The most common outcomes included otitis media (4.2%) and emergency department visits (2.6%). Serious events were extremely rare, with very small case counts (Tables 2-3 ). Infant follow-up was censored during the 30-day follow-up window after 5.4% of doses; 0.9% censoring events were due to a subsequent RV dose within 30 days, and the remainder were administratively censored due to plan disenrolment or end of study period. Table 3) .
TA B L E 1 Characteristics of diphtheria-tetanus-pertussis (DTaP) vaccine receivers by concurrent rotavirus vaccine (RV) receipt at the first dose received DTaP, diphtheria-tetanus-pertussis vaccine; RV1, two-dose monovalent rotavirus vaccine; RV5, three-dose pentavalent rotavirus vaccine; RV+DTaP, RV, and DTaP concurrently received on the same day; SD, standard deviation. a RV1 and RV5 subsets do not sum to the Any RV group due to the exclusion of RV recipients receiving different formulations for the first and second doses.
TA (Table S3) .
We did not observe consistently elevated rates of other outcomes associated with RV (Table 2) , except for small, potentially elevated rates of otitis media, although the relative increases were quite small-pooled HR = 1.04 (95% CI 1.02, 1.06)-but the associations varied by dose (P for homogeneity < 0.001), with essentially null associations with dose 1 and 3, but an elevated association observed after dose 2, HR = 1.11 (95% CI 1.08, 1.15). This association was less pronounced in RV5 compared to RV1, with a pooled HR of 0.92 (95% CI, 0.89, 0.95) and was consistent across doses 1 and 2
(P for homogeneity = 0.53) ( Table 3) .
Otitis media incidence varies by several factors, including sex 28 and geography; additionally, otitis media incidence decreased after the March 2010 introduction of the pneumococcal conjugate vaccine. 28 However, in post hoc subgroup analyses, the observed otitis media association with RV dose 2, and specifically with RV1, was consistent across levels of sex, US region, and time period (Table S4) .
Overall, RV was associated with some reduced rates of cer- (Table S3 ).
| COMMENT
| Principal findings
In this large study of US infants receiving DTaP with or without RV, we did not observe a consistently increased risk of intussusception associated with RV in the 30 days post-vaccination for either vaccine formulation, and overall, the number of cases and rates were very low. Rates of intussusception varied with age, and the estimates were consistent with a null finding across the 3 doses, generally given at 2, 4, and 6 months of age; however, the 30-day HR at dose 2 was higher than the other doses, but the small number of cases and imprecision around the estimate resulted in similar, null conclusions.
While these data do not indicate evidence of increased intussusception risks overall equal to previously published studies, the dose 2 estimate may be consistent with a small increase observed in previous studies in various populations.
| Strengths of the study
In our cohort study, we restricted to infants who received DTaP immunisation in our study, attempting to create a more homogenous Multivariable models adjusted for: child's age (categorised in 10-week increments), year of vaccine administration, sex, US region, and concurrent vaccination receipt (hepatitis B, Haemophilus influenzae type B, Pneumococcal, polio, influenza). *P for homogeneity <0.05. a denotes too few cases for models to converge. 
TA B L E 2 (Continued)
TA B L E 3 Association of adverse events with pentavalent rotavirus vaccination (RV5) with concurrent diphtheria-tetanus-pertussis (DTaP) vs monovalent rotavirus vaccination (RV1) with concurrent DTaP
| Limitations of the data
Since insurance billings claims represent the basis for payment and not detailed clinical records, we were unable to measure the severity of intussusception or other outcomes, and some outcomes may be misclassified due to coding errors. In addition, our sample is limited to those with employer-based insurance and may not be generalisable to those with Medicaid, the uninsured, or non-US children. As natural intussusception rates and rotavirus infection rates can differ widely in different countries, climates, and populations, continued investigation in diverse settings is needed.
By restricting our analysis to those receiving DTaP, the generalisability of the study may be limited to only children receiving DTaP; however, DTaP coverage is extremely high, and this restriction anchors RV receivers and non-receivers at equivalent points in their clinical experience, implicitly controlling for several important potential confounders such as vaccine-avoiding behaviour and attitudes, access to health care, current health status, and vaccine schedule-keeping behaviour-major confounders of studies comparing vaccine receivers to non-receivers. However, by requiring DTaP co-administration, we would be unable to disentangle any synergistic effects or interactions of RV and DTaP administered together.
In addition, unmeasured confounding may remain which was not accounted for by the study design or adjustment variables, and even after anchoring RV receivers and non-receivers on DTaP receipt, the mean age at RV+DTaP doses tended to be slightly younger than at doses of DTaP received alone. Vaccine co-administration varied between RV and non-RV groups; this may be partially explainable by time trends of RV introduction and (eg, PCV and RV, particularly RV1, were more common later in the study period) or schedules (eg, influenza vaccine is indicated in infants 6 + months, generally overlapping with RV5's third dose but not earlier doses), but there remains a wide range of vaccine uptake not always aligned with recommendations.
While the use of large insurance data allows for a large study population of children throughout the US treated in a variety of settings, our case counts of intussusception and some other rare outcomes were quite small-particularly in the 7-day analysesoccasionally making direct comparisons between treatment groups difficult. Our observed intussusception rate was less than that observed in other studies 18 ; medical chart validation of exposures and outcomes was not possible due to the deidentified nature of the data source, and we may have missed some true outcome cases if the insurance billing claim was incomplete or incorrectly coded.
While any potential misclassification of study outcomes was un- 
| Interpretation
The results from our cohort study differ somewhat from the generally increased intussusception risks reported in previous selfcontrolled studies 12, 30 which may be confounded by the changing within-person risk of intussusception during infanthood, and user vs non-user cohort designs may be confounded by differences between vaccine receivers and non-receivers.
We observed a small increased risk of otitis media associated with RV dose 2 in both 7-day and 30-day analysis. Otitis media has previously been reported as potentially being associated with rotavirus infection in small studies 31, 32 as rotavirus can colonise the upper respiratory tract, including the inner ear; additionally, otitis media had been observed as an unsolicited adverse event in RV trials. 33 While we describe a relative increase in otitis media risk associated with RV dose 2, the magnitude of the effect was quite small and was not consistent across all doses. Otitis media was quite common in the infants and is generally considered a non-serious event. In addition, an increased association of RV with meningitis was observed after dose 2; this association was not consistent across doses and was based on very small sample sizes (with only two cases in the DTaP alone group), resulting in substantial imprecision of the estimate and very wide confidence intervals.
We did observe some small protective associations for some outcomes: it was not our a priori intention to evaluate protective effects, so we choose to not emphasise them, yet the slight reduction in seizures we observed is consistent with previous research. 34, 35 While the 30-day post-vaccination follow-up is short, the reductions in hospitalisations and emergency department visits may be due to the effectiveness of the vaccine in preventing rotavirus-associated illness.
| CON CLUS IONS
Overall, we did not demonstrate an association between RV and serious adverse events, and the safety was comparable between the two RV formulations, though many events were rare. RV may be associated with a small increased risk of otitis media, but further research is necessary to confirm this association.
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